Masimo (NASDAQ: MASI) and University Hospitals (UH), one of the largest healthcare systems in northeastern Ohio, today jointly announced Masimo SafetyNet ™, an innovative and cost-effective patient management system scalable designed to help clinicians care for patients from a distance.
This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20200325005795/en/
Masimo SafetyNet ™ (Photo: Business Wire)
Telehealth solution combines Radius PPG ™ wireless pulse oximetry, driven by Masimo SET technology® Measure-through Motion and Low Perfusion ™, with Doctella ™, a secure remote monitoring platform for home patients accessible from their smartphone or iOS or Android smart device.
The health emergency of COVID-19 has significantly increased the demand for remote monitoring and patient engagement solutions in multiple settings. To proactively prepare for a sharp increase in the number of COVID-19 patients while ensuring the safety of other patients and providers, this new solution allows UH and other hospitals to extend patient monitoring to home or other establishments temporarily set up to meet increased demand. Current WHO guidelines recommend monitoring oxygen saturation (SpO2), respiratory rate (FR) and temperature of patients suspected or confirmed to have COVID-19, and Masimo and UH are responding to this increased demand by adapting existing technology to provide a secure remote solution.
Masimo SafetyNet offers healthcare teams a single platform solution that combines a secure cloud-based monitoring platform with clinically proven pulse oximetry SET®, which is expected to be used by more than 200 million patients each year. 1 Besides SpO2, Radius PPG is able to continuously monitor the pulse rate (FP), the perfusion index, PVi® and RRp®, the respiratory rate of the photoplethysmograph.
Patients can be discharged home with a multi-day supply of single-use Radius PPG sensors and access to the Doctella mobile app, designed for easy and intuitive patient use via a digital home care plan, or CareProgram, which aligns with expert advice on COVID-19. Radius PPG shares its SpO data2, PR, and RRp with Doctella using secure Bluetooth wireless technology®. In addition, Doctella may manually collect other physiological data, such as temperature. Twice a day, or as directed, the Doctella CareProgram actively asks patients to answer questions such as “Are you having trouble breathing?” “And” what is your temperature? ”, And securely transmits these responses along with physiological monitoring data to hospital clinicians for evaluation. The Doctella Clinician Portal makes it easy for providers to track patient compliance, helping them determine when intervention may be needed, as well as providing information to help providers prioritize patients. CarePrograms are fully customizable to suit the protocols of each facility, the needs of each patient, and any changes in COVID-19 guidelines, and can be updated by providers via the cloud, even after deployment, for maximum flexibility as situations evolve.
“We appreciate Masimo’s immediate collaboration in the implementation of this innovative platform which will considerably help us to increase remote monitoring and meet the demand for patient care while addressing capacity and safety problems”, a explained Peter Pronovost, MD, director of clinical transformation at UH. “For our patients with congestive heart failure or chronic obstructive pulmonary disease (COPD), we can provide them with this remote monitoring capability so they don’t risk COVID-19 infection by being close to potentially patients infected. Likewise, for patients with a confirmed diagnosis of COVID-19, we can appropriately isolate them from other patients while ensuring their access to first-rate care to manage their health throughout the recovery process. ”
Joe Kiani, founder and CEO of Masimo, said, “We thank the nurses and doctors who work so courageously in the hospitals taking care of all of us during this pandemic. We are delighted to be able to help them effectively screen and care for COVID-19 patients in the best possible way using Masimo SafetyNet. It has been a pleasure to work with UH to provide this technology to the healthcare industry to help them meet the challenges they face in these unprecedented times. ”
“This alliance illustrates UH’s strategy for improving the health of the population,” said Daniel I. Simon, MD, chief clinical and scientific officer of UH and president of UH Cleveland Medical Center. “By deploying ‘outside to inside’ tactics and forming this partnership with Masimo, our patients receive cutting-edge therapeutic approaches while we help improve the product for future users and for the transformation of the industry. ”
UH plans to start piloting this system next week.
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide range of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. . Our mission is to improve the therapeutic results for patients and reduce the cost of care. Masimo SET pulse oximetry® Measure-through Motion and Low Perfusion ™, introduced in 1995, has proven to outperform other pulse oximetry technologies in more than 100 independent and objective studies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in newborns,3 improve screening for critical congenital heart disease in newborns4, and, when used as part of continuous monitoring with Masimo’s Patient SafetyNet ™ in post-surgery rooms, reduce team activations, SSI transfers and costs.5-7 It is estimated that Masimo SET® is used on over 200 million patients in large hospitals and other healthcare facilities around the world1, and that it is the main pulse oximetry in 9 of the 10 largest hospitals listed in the U.S. News and World Report Best Hospitals Honor Roll of 2019-20.8 Masimo continues to perfect SET® and, in 2018, announced that the accuracy of SpO2 on RD SET sensors® in movement conditions had been significantly improved, reassuring clinicians even more than SpO values2 they rely on accurately reflect a patient’s physiological status. In 2005, Masimo launched rainbow pulse CO-oximetry technology®, for non-invasive and continuous monitoring of blood components that previously could only be measured by invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC ™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), the pleth variability index (Pleth Variability Index, PVi®), RPVi ™ (rainbow® PVi), and the Oxygen Reserve Index, ORi ™. In 2013, Masimo launched the Root patient monitoring and connectivity platform®, built entirely to be as flexible and extensible as possible to facilitate the addition of other Masimo and third-party surveillance technologies; key Masimo additions are Next Generation SedLine brain function monitoring®, O3 regional oximetry® and ISA ™ capnography with NomoLine sampling lines®. The Pulse CO-Oximeters range® Masimo’s continuous and ad hoc monitoring system includes devices designed to be used in a variety of clinical and non-clinical scenarios, including portable no-clip technology, such as Radius-7® and Radius PPG ™, portable devices such as Rad-67 ™, fingertip pulse oximeters such as MightySat® Rx, and devices used in hospitals and at home such as Rad-97®. Masimo hospital automation and connectivity solutions are centered on the Iris platform®, and include Iris Gateway®, Patient SafetyNet, Replica ™, Halo ION ™, UniView ™ and Doctella ™. More information about Masimo and its products is available at www.masimo.com. Clinical studies published on Masimo products are available at www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received 510 (k) clearance from the FDA and are not for sale in the United States. Use of the Patient SafetyNet trademark is licensed from the University HealthSystem Consortium.
Estimate: Masimo archive data.
Published clinical studies on pulse oximetry and the benefits of Masimo SET technology® can be found on our website at http://www.masimo.com. Comparative studies include independent, objective studies, consisting of abstracts presented at scientific meetings, and peer-reviewed journal articles.
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after competition study. Anesthesiology. 2010; 112 (2): 282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. July. 2016; 42 (7): 293-302.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. Feb 2011; 100 (2): 188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. Jan 8, 2009; 338.
About University Hospitals
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 50 health centers and ambulatory facilities, and 200 doctors’ offices in 16 counties in northern Ohio. The system’s flagship university medical center, University Hospitals Cleveland Medical Center, located in the University Circle of Cleveland, is affiliated with the Faculty of Medicine of Case Western Reserve University. The main campus also includes the University Hospitals Rainbow Babies & Children’s Hospital, ranked among the best children’s hospitals in the country; University Hospitals MacDonald Women’s Hospital, the only hospital for women in Ohio; University Hospitals Harrington Heart & Vascular Institute, a national high-volume reference center for complex cardiovascular procedures; and University Hospitals Seidman Cancer Center, which is part of the Case Comprehensive Cancer Center designated by the NCI. UH is home to some of the country’s most prestigious clinical and research programs, including cancer, pediatrics, women’s health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. The UH Cleveland Medical Center has always been among the top performers in national ranking surveys, including “America’s Best Hospitals” from the U.S. News & World Report. UH is also home to the Harrington Discovery Institute at University Hospitals – which is part of the Harrington project for discovery and development. UH is one of the largest employers in northeast Ohio with 28,000 doctors and employees. Promote the science of health and the art of compassion is UH’s vision for the well-being of its patients in the future, and the organization’s unwavering mission is to Heal. Teach. Discover. Follow UH on LinkedIn, Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, visit UHhospitals.org.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements forecasts include, among others, statements regarding the potential effectiveness of Masimo SafetyNet ™, Radius PPG ™, Doctella ™, SET®, and RRp®. These forward-looking statements are based on current expectations regarding future events that concern us, and are subject to risks and uncertainties, all difficult to predict and often beyond our control, and likely to cause actual results to vary materially and negatively. compared to those expressed in our forward-looking statements in response to various risk factors, including, without limitation: the risks associated with our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique non-invasive measurement technologies, including Masimo SafetyNet, Radius PPG, Doctella, SET®, and RRp, contribute to positive clinical results and patient safety; risks associated with our belief that Masimo’s revolutionary and non-invasive medical advances provide cost-effective solutions and unique benefits; the risks associated with COVID-19; as well as other factors discussed in the “Risk Factors” section in our most recent reports filed with the Securities and Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at address www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether these expectations will prove to be correct. All forward-looking statements contained in this press release are expressly covered in their entirety by the foregoing warnings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today. We do not accept any obligation to update, modify or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether in response to new information, future events or for any other reason, unless required by applicable securities laws.
The text of the press release resulting from a translation should in no way be considered official. The only version of the press release that is authentic is that of the press release in its original language. The translation will always have to be compared with the source text, which will set precedent.